Adrian JTLDR: CytexOrtho, a pre-clinical stage medical device company based in Durham, North Carolina, has won the inaugural OrthoPitch Technology Competition at AAOS 2024. The company’s ReNew Hip implant, which is still in clinical trials, is designed to restore the hip joint naturally rather than replacing it. The implant slowly absorbs into the body while cells move into gaps in its layers to form functional tissue. The device has FDA Breakthrough Device designation.
Durham, North Carolina–based CytexOrtho won the inaugural OrthoPitch Technology Competition at AAOS 2024 this week. A pre-clinical stage medical device company, CytexOrtho’s ReNew Hip implant is designed to restore the joint naturally rather than replace it.
CytexOrtho founder and CEO Bradley Estes explained during the pitch competition that surgeons remove only the damaged tissue, replacing it with the implant. The implant restores the joint to its proper form and contour.
“The ReNew Hip implant is comprised of two very special components — one is a 3D-woven textile and the other is a high-precision, Tru3D printed component,” Estes said during the pitch event, as recounted in an AAOS news release posted on Feb. 14. “The integration of these two components gives us an implant that not only recreates the form and contour of a healthy articular joint surface but also recreates the function of articular cartilage and bone.”
Presented by AAOS and sponsored by medical device consulting firm MCRA , OrthoPitch kicked off in July 2023 with a call for entries. The AAOS Devices, Biologics and Technology Committee conducted a multi-staged review process.
CytexOrtho won in a live online vote.
